Isomorphic Labs says it has raised $5 billion in Series C funding. In its announcement dated Nov. 17, the AI drug-discovery company says Greenoaks and Sequoia Capital co-led the round, "alongside Andreessen Horowitz (a16z) and several other new investors, with continued significant investment from Alphabet."
What the company announced
- Existing investors also took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
- Isomorphic says the money is for "scaling its proprietary drug design engine (IsoDDE) and therapeutic candidate pipeline designed with AI to deliver the next generation of medicines for patients."
- Its homepage says: "Our lead internal programs are now advancing towards the clinic."
What the coverage adds
TechCrunch reported that Isomorphic is seeking to take drug candidates into clinical trials, and that the company said its program has produced "positive preclinical results" in oncology and immunology. We did not find that claim in the announcement text we read, so treat it as the report's.
The valuation is not disclosed
Isomorphic did not disclose a valuation for this round, according to the same report. It adds that Bloomberg reported earlier this month that the company was looking to raise at a $50 billion valuation. We did not read that report.
We cannot say whether the round closed at that figure, and the announcement does not say.
What this means for you
Nothing changes for users today. Isomorphic describes itself as building a drug design engine and a pipeline of candidates, and its announcement is about funding, not a product you can use.
For other big AI rounds we are tracking, see OpenAI's reported $30B round and the FTC's reported subpoenas to OpenAI and Anthropic.
What we do not know
- The valuation the round was priced at.
- How the $5 billion is split between investors, or how much comes from Alphabet.
- When any candidate will start clinical trials, or what the preclinical results show.



